Research analysts at Ladenburg Thalmann Financial Services assumed coverage on shares of Eyenovia (NASDAQ:EYEN) in a research report issued on Tuesday, February 20th, Marketbeat reports. The brokerage set a “buy” rating and a $35.00 price target on the stock. Ladenburg Thalmann Financial Services’ target price indicates a potential upside of 296.38% from the stock’s previous close.
Separately, Roth Capital began coverage on shares of Eyenovia in a research note on Tuesday, February 20th. They set a “buy” rating and a $20.00 price target on the stock.
Shares of Eyenovia (NASDAQ:EYEN) traded down $0.18 during trading on Tuesday, hitting $8.83. 12,924 shares of the stock were exchanged, compared to its average volume of 28,921. Eyenovia has a twelve month low of $7.32 and a twelve month high of $10.74.
Eyenovia Company Profile
Eyenovia, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of ophthalmology products utilizing its piezo-print technology to deliver micro-doses of active pharmaceutical ingredients (micro-therapeutics) to the eye. Its product candidates include MicroProst, MicroStat, MicroTears and MicroPine.
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.